Formulation: A solid
Formal Name: 4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine, monohydrochloride
Purity: ≥98%
Formula Markup: C17H15N3O2 • HCl
Formula Weight: 329,8
Shelf life (days): 1460
CAS Number: 192065-56-8
Notes: GYKI 52466 is an allosteric AMPA receptor antagonist.{61464} It selectively inhibits AMPA-induced inward currents (IC50 = 7.5 µM) over NMDA- or GABA-induced inward currents in primary rat hippocampal neurons at 50 µM but also inhibits kainate-induced inward currents in the same cells (IC50 = 11 µM).{61465} GYKI 52466 (10 µM) reduces the amplitude of spontaneous excitatory postsynaptic currents (EPSCs) in the same cells. It increases the latency to seizure onset and reduces mortality in a rat model of generalized tonic-clonic seizures induced by 4-aminopyridine (4-AP; Item No. 18511) when administered at doses of 25 and 50 mg/kg.{61464} GYKI 52466 (30 mg/kg) prevents neuronal damage in the CA1 region of the hippocampus in a rat model of global ischemia-reperfusion injury induced by four-vessel occlusion.{61466}
English
Deutsch
